Alto Neuroscience Raises $50 Million in Private Placement Led by Perceptive Advisors
Reuters
Oct 20, 2025
<a href="https://laohu8.com/S/ANRO">Alto Neuroscience</a> Raises $50 Million in Private Placement Led by Perceptive Advisors
Alto Neuroscience Inc. has announced a $50 million private placement financing led by Perceptive Advisors, with participation from both new and existing biotech-focused investors, including Commodore Capital, Vestal Point Capital, Vivo Capital, and a large biotech-dedicated investor. The proceeds are expected to accelerate the development of ALTO-207 for treatment-resistant depression. As part of the transaction, Alto has agreed to file a registration statement with the SEC to register the resale of the shares of common stock and shares issuable upon the exercise of pre-funded warrants issued in the private placement. CEO Amit Etkin highlighted that the financing will support the advancement of Alto's precision psychiatry platform and clinical pipeline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020503608) on October 20, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.